1-磷酸鞘氨醇在膿毒癥診療中的應用前景_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

徐宇治 ,  孫立群

南京醫科大學第二附屬醫院重癥醫學科（江蘇南京 210011）;

Corresponding?author：

孫立群, Email: liqunsun@njmu.edu.cn

Keywords：

DOI：

10.7507/1671-6205.202202017

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 徐宇治, 孫立群. 1-磷酸鞘氨醇在膿毒癥診療中的應用前景. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(5): 370-373. doi: 10.7507/1671-6205.202202017 Copy

1.	Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock. Lancet, 2018, 392(10141): 75-87.
2.	Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet, 2020, 395(10219): 200-211.
3.	Esposito S, De Simone G, Boccia G, et al. Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist, 2017, 10: 204-212.
4.	Opal SM, Wittebole X. Biomarkers of infection and sepsis. Crit Care Clin, 2020, 36(1): 11-22.
5.	Kurano M, Tsukamoto K, Shimizu T, et al. Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes, 2020, 69(5): 867-881.
6.	李建, 李文哲, 王鑫, 等. 血清 1-磷酸鞘氨醇水平動態變化對膿毒性休克短期預后的預測價值. 標記免疫分析與臨床, 2020, 27(5): 794-798.
7.	Winkler MS, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care, 2015, 19: 372.
8.	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
9.	Fan YW, Chen JM, Liu D, et al. HDL-S1P protects endothelial function and reduces lung injury during sepsis in vivo and in vitro. Int J Biochem Cell Biol, 2020, 126: 105819.
10.	Ziegler AC, Müller T, Gr?ler MH. Sphingosine 1-phosphate in sepsis and beyond: Its role in disease tolerance and host defense and the impact of carrier molecules. Cell Signal, 2021, 78: 109849.
11.	Jozefczuk E, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res, 2020, 156: 104793.
12.	Ksi??ek M, Chacińska M, Chabowski A, et al. Sources, metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res, 2015, 56(7): 1271-1281.
13.	Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol, 2019, 31(9): 617-625.
14.	Baeyens AAL, Schwab SR. Finding a way out: S1P signaling and immune cell migration. Annu Rev Immunol, 2020, 38: 759-784.
15.	Wang X, Wang F. Vascular protection by high-density lipoprotein-associated sphingosine-1-phosphate. J Geriatr Cardiol, 2017, 14(11): 696-702.
16.	Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem, 2001, 276(34): 31780-31785.
17.	Dennhardt S, Finke KR, Huwiler A, et al. Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(4): 774-781.
18.	Burg N, Swendeman S, Worgall S, et al. Sphingosine 1-phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. Arthritis Rheumatol, 2018, 70(11): 1879-1889.
19.	Song F, Hou JC, Chen ZC, et al. Sphingosine-1-phosphate receptor 2 signaling promotes caspase-11-dependent macrophage pyroptosis and worsens escherichia coli sepsis outcome. Anesthesiology, 2018, 129(2): 311-320.
20.	Hou JC, Chen QX, Wu XL, et al. S1PR3 signaling drives bacterial killing and is required for survival in bacterial sepsis. Am J Respir Crit Care Med, 2017, 196(12): 1559-1570.
21.	Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol, 2018, 20(5): e12836.
22.	Martín-Fernández M, Tamayo-Velasco á, Aller R, et al. Endothelial dysfunction and neutrophil degranulation as central events in sepsis physiopathology. Int J Mol Sci, 2021, 22(12): 6272.
23.	王穎勤, 鐘鳴, 諸杜明. 鞘氨醇-1-磷酸在膿毒癥中調節作用的研究進展. 中國臨床醫學, 2018, 25(6): 977-982.
24.	Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock, 2016, 45(3): 259-270.
25.	Xiong YQ, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol, 2014, 378: 85-105.
26.	Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem, 2004, 279(23): 24692-24700.
27.	范怡雯. 探究高密度脂蛋白相關 1—磷酸鞘氨醇在膿毒癥中對肺血管內皮功能的作用及其機制 [D]. 上海交通大學, 2020.
28.	Cao CC, Dai L, Mu JY, et al. S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1/2-dependent cPLA₂ phosphorylation. Cell Signal, 2019, 53: 151-161.
29.	Iba T, Umemura Y, Wada H, et al. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment. Arch Med Res, 2021, 52(8): 788-797.
30.	Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost, 2020, 46(1): 89-95.
31.	Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost, 2019, 17(2): 283-294.
32.	Zeng Y, Adamson RH, Curry FR, et al. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol, 2014, 306(3): H363-H372.
33.	Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care, 2019, 23(1): 16.
34.	Kuzmich NN, Sivak KV, Chubarev VN, et al. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel), 2017, 5(4): 34.
35.	Zhang HF, Zhang HB, Wu XP, et al. Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK/MK2 signaling. Acta Pharmacol Sin, 2020, 41(10): 1348-1356.
36.	Winkler MS, Nierhaus A, Poppe A, et al. Sphingosine-1-phosphate: a potential biomarker and therapeutic target for endothelial dysfunction and sepsis?. Shock, 2017, 47(6): 666-672.
37.	Wang XW, Chen SH, Xiang H, et al. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med, 2021, 25(6): 2740-2749.
38.	Hu SP, Pi QZ, Xu XD, et al. Disrupted eNOS activity and expression account for vasodilator dysfunction in different stage of sepsis. Life Sci, 2021, 264: 118606.
39.	Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol, 2017, 39(5): 517-528.
40.	Kerage D, Gombos RB, Wang SM, et al. Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries. Vascul Pharmacol, 2021, 140: 106874.
41.	Wu XL, Hou JC, Li H, et al. Inverse correlation between plasma sphingosine-1-phosphate and ceramide concentrations in septic patients and their utility in predicting mortality. Shock, 2019, 51(6): 718-724.
42.	Zhang L, Wang HD. FTY720 in CNS injuries: molecular mechanisms and therapeutic potential. Brain Res Bull, 2020, 164: 75-82.
43.	Kuai F, Wang L, Su JH, et al. Exploring the protective role and the mechanism of sphingosine 1 phosphate in endotoxic cardiomyocytes. Shock, 2019, 52(4): 468-476.

1. Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock. Lancet, 2018, 392(10141): 75-87.
2. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet, 2020, 395(10219): 200-211.
3. Esposito S, De Simone G, Boccia G, et al. Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist, 2017, 10: 204-212.
4. Opal SM, Wittebole X. Biomarkers of infection and sepsis. Crit Care Clin, 2020, 36(1): 11-22.
5. Kurano M, Tsukamoto K, Shimizu T, et al. Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes, 2020, 69(5): 867-881.
6. 李建, 李文哲, 王鑫, 等. 血清 1-磷酸鞘氨醇水平動態變化對膿毒性休克短期預后的預測價值. 標記免疫分析與臨床, 2020, 27(5): 794-798.
7. Winkler MS, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care, 2015, 19: 372.
8. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
9. Fan YW, Chen JM, Liu D, et al. HDL-S1P protects endothelial function and reduces lung injury during sepsis in vivo and in vitro. Int J Biochem Cell Biol, 2020, 126: 105819.
10. Ziegler AC, Müller T, Gr?ler MH. Sphingosine 1-phosphate in sepsis and beyond: Its role in disease tolerance and host defense and the impact of carrier molecules. Cell Signal, 2021, 78: 109849.
11. Jozefczuk E, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res, 2020, 156: 104793.
12. Ksi??ek M, Chacińska M, Chabowski A, et al. Sources, metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res, 2015, 56(7): 1271-1281.
13. Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol, 2019, 31(9): 617-625.
14. Baeyens AAL, Schwab SR. Finding a way out: S1P signaling and immune cell migration. Annu Rev Immunol, 2020, 38: 759-784.
15. Wang X, Wang F. Vascular protection by high-density lipoprotein-associated sphingosine-1-phosphate. J Geriatr Cardiol, 2017, 14(11): 696-702.
16. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem, 2001, 276(34): 31780-31785.
17. Dennhardt S, Finke KR, Huwiler A, et al. Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(4): 774-781.
18. Burg N, Swendeman S, Worgall S, et al. Sphingosine 1-phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. Arthritis Rheumatol, 2018, 70(11): 1879-1889.
19. Song F, Hou JC, Chen ZC, et al. Sphingosine-1-phosphate receptor 2 signaling promotes caspase-11-dependent macrophage pyroptosis and worsens escherichia coli sepsis outcome. Anesthesiology, 2018, 129(2): 311-320.
20. Hou JC, Chen QX, Wu XL, et al. S1PR3 signaling drives bacterial killing and is required for survival in bacterial sepsis. Am J Respir Crit Care Med, 2017, 196(12): 1559-1570.
21. Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol, 2018, 20(5): e12836.
22. Martín-Fernández M, Tamayo-Velasco á, Aller R, et al. Endothelial dysfunction and neutrophil degranulation as central events in sepsis physiopathology. Int J Mol Sci, 2021, 22(12): 6272.
23. 王穎勤, 鐘鳴, 諸杜明. 鞘氨醇-1-磷酸在膿毒癥中調節作用的研究進展. 中國臨床醫學, 2018, 25(6): 977-982.
24. Ince C, Mayeux PR, Nguyen T, et al. The endothelium in sepsis. Shock, 2016, 45(3): 259-270.
25. Xiong YQ, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol, 2014, 378: 85-105.
26. Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem, 2004, 279(23): 24692-24700.
27. 范怡雯. 探究高密度脂蛋白相關 1—磷酸鞘氨醇在膿毒癥中對肺血管內皮功能的作用及其機制 [D]. 上海交通大學, 2020.
28. Cao CC, Dai L, Mu JY, et al. S1PR2 antagonist alleviates oxidative stress-enhanced brain endothelial permeability by attenuating p38 and Erk1/2-dependent cPLA₂ phosphorylation. Cell Signal, 2019, 53: 151-161.
29. Iba T, Umemura Y, Wada H, et al. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment. Arch Med Res, 2021, 52(8): 788-797.
30. Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost, 2020, 46(1): 89-95.
31. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost, 2019, 17(2): 283-294.
32. Zeng Y, Adamson RH, Curry FR, et al. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol, 2014, 306(3): H363-H372.
33. Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care, 2019, 23(1): 16.
34. Kuzmich NN, Sivak KV, Chubarev VN, et al. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel), 2017, 5(4): 34.
35. Zhang HF, Zhang HB, Wu XP, et al. Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK/MK2 signaling. Acta Pharmacol Sin, 2020, 41(10): 1348-1356.
36. Winkler MS, Nierhaus A, Poppe A, et al. Sphingosine-1-phosphate: a potential biomarker and therapeutic target for endothelial dysfunction and sepsis?. Shock, 2017, 47(6): 666-672.
37. Wang XW, Chen SH, Xiang H, et al. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med, 2021, 25(6): 2740-2749.
38. Hu SP, Pi QZ, Xu XD, et al. Disrupted eNOS activity and expression account for vasodilator dysfunction in different stage of sepsis. Life Sci, 2021, 264: 118606.
39. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol, 2017, 39(5): 517-528.
40. Kerage D, Gombos RB, Wang SM, et al. Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries. Vascul Pharmacol, 2021, 140: 106874.
41. Wu XL, Hou JC, Li H, et al. Inverse correlation between plasma sphingosine-1-phosphate and ceramide concentrations in septic patients and their utility in predicting mortality. Shock, 2019, 51(6): 718-724.
42. Zhang L, Wang HD. FTY720 in CNS injuries: molecular mechanisms and therapeutic potential. Brain Res Bull, 2020, 164: 75-82.
43. Kuai F, Wang L, Su JH, et al. Exploring the protective role and the mechanism of sphingosine 1 phosphate in endotoxic cardiomyocytes. Shock, 2019, 52(4): 468-476.

Previous Article
慢性阻塞性肺疾病肺氣腫表型影像學特征與發生機制研究進展
Next Article
溶瘤病毒在肺癌治療中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

1-磷酸鞘氨醇在膿毒癥診療中的應用前景

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content